MetaCap

Cellectis S.A. (CLLS) vs Unicycive Therapeutics (UNCY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Unicycive Therapeutics (UNCY) has outperformed Cellectis S.A. (CLLS) over the past year, losing 38.0% versus a loss of 80.4%. Over five years, UNCY leads with a -88.5% price change compared with -89.4% for CLLS. Unicycive Therapeutics is the larger company by market cap ($97.8 million vs $92.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CLLS-80.36%UNCY-37.96%
+65%-11%-87%
Nov 21, 20251 yearNov 20, 2026
CLLS-89.66%UNCY-87.07%
+18%-38%-95%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CLLS versus UNCY key metrics
MetricCLLSUNCY
Share price$0.9209$3.35
Market cap$92.76M$97.77M
1-day change-7.89%-5.10%
YTD return-80.97%-41.94%
1-year return-80.36%-37.96%
5-year return-89.40%-88.53%
Forward P/E—4.86
EPS (TTM)$-1.26$-1.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$72.95M—
Revenue growth (YoY)+75.76%—
Net income (latest FY)$-67.59M$-26.55M
Gross margin100.00%—
Operating margin-45.34%—
Net margin-92.66%—
52-week high$5.45$8.74
52-week low$0.881$3.33
Distance from 52-week high-83.10%-61.67%
Analyst consensusbuystrong_buy
Avg. price target upside+497.24%+685.07%
Average volume115.00K963.80K
Shares outstanding72.73M29.18M
Employees22421
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • UNCY has outperformed CLLS by 42.4 percentage points over the past year.

About Cellectis S.A.

CLLS stock →

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).

Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees

About Unicycive Therapeutics

UNCY stock →

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

CLLS vs UNCY FAQ

Which is bigger, Cellectis S.A. or Unicycive Therapeutics?

Unicycive Therapeutics (UNCY) is larger, with a market capitalization of $97.77M compared with $92.76M for Cellectis S.A. (CLLS).

Which stock has performed better over the past year, CLLS or UNCY?

UNCY returned -37.96% over the past 12 months, compared with -80.36% for CLLS (price return, excluding dividends). Past performance does not predict future results.

Are Cellectis S.A. and Unicycive Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons